U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Mon Oct 21 19:44:27 UTC 2019
Edited
by admin
on Mon Oct 21 19:44:27 UTC 2019
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
0UY97CSG1T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2B6
Common Name English
1,4-CINEOLE 2-EXO-MONOOXYGENASE
Common Name English
CYP2B6
Common Name English
CYTOCHROME P 450 2B6
Common Name English
HUMAN CYTOCHROME P450 2B6
Common Name English
Code System Code Type Description
PUBCHEM
121225712
Created by admin on Mon Oct 21 19:44:27 UTC 2019 , Edited by admin on Mon Oct 21 19:44:27 UTC 2019
PRIMARY
CAS
330207-11-9
Created by admin on Mon Oct 21 19:44:27 UTC 2019 , Edited by admin on Mon Oct 21 19:44:27 UTC 2019
PRIMARY
UNIPROT
P20813
Created by admin on Mon Oct 21 19:44:27 UTC 2019 , Edited by admin on Mon Oct 21 19:44:27 UTC 2019
PRIMARY
Related Record Type Details
INHIBITOR -> TARGET
MINOR
NON-INDUCER -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
Rifamycin is an inducer of CYP3A4 and CYP2B6 but not CYP1A2 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant induction of these enzymes in vivo is unlikely.
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
IC50
NON-INHIBITOR -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
Ki
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
IC50
INDUCER -> METABOLIC ENZYME
tafamidis induced CYP2B6 in vitro with an EC50 of 25 ?M.
EC50
INDUCER -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
INHIBITOR -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
CYP2B6 preferentially metabolized (S)-methadone,
SUBSTRATE -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
TISSUE EXPRESSION -> PARENT
NON-SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
TISSUE EXPRESSION -> PARENT
INDUCER -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
ACTIVATOR
SUBSTRATE -> METABOLIC ENZYME
MINOR
INDUCER -> TARGET
INDUCER -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
MODERATE
SUBSTRATE -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
IC50
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INDUCER -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
WEAK INHIBITOR
NON-SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
IC50
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL